4Moving Biotech Secures FDA IND Clearance for First-in-Class Intra-Articular GLP-1 Agonist in Osteoarthritis
核心洞察
4Moving Biotech received FDA IND clearance for 4P004 (搜索), enabling expansion of the Phase 2a INFLAM MOTION trial into the United States alongside existing sites in Europe and Canada.
The company is advancing the first clinical proof of concept for a first-in-class intra-articular GLP-1 receptor (搜索) agonist targeting disease modification in osteoarthritis (搜索).
The INFLAM MOTION trial will enroll 129 patients with knee osteoarthritis (搜索) and synovitis (搜索), with pain assessment at Week 4 as the primary endpoint and structural MRI evaluation at Week 12.
4Moving Biotech announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for 4P004 (搜索), a first-in-class intra-articular GLP-1 receptor (搜索) agonist being developed as a disease-modifying therapy for osteoarthritis (搜索). The FDA clearance enables the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States, joining existing sites in Europe and Canada.
The regulatory milestone positions 4Moving Biotech as a front-runner in developing the first disease-modifying osteoarthritis (搜索) drug (DMOAD) for a condition affecting more than 600 million people worldwide who currently lack approved therapies that alter disease course. Preclinical studies have demonstrated that 4P004 (搜索) can modulate multiple biological markers across the whole joint, supporting its potential as a first-in-class DMOAD capable of slowing structural impairment and improving joint function.
"FDA's clearance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe, Canada, and the United States," said Luc Boblet, Chief Executive Officer of 4Moving Biotech. "This milestone strengthens our position as one of the most advanced DMOAD developers globally and brings us closer to demonstrating the transformative potential of 4P004 (搜索) for the millions of patients worldwide who currently have no disease-modifying options."
Novel Therapeutic Approach
4P004 (搜索) represents a unique therapeutic approach as a GLP-1 receptor (搜索) agonist administered intra-articularly, allowing specific targeting of the diseased joint and joint tissues. This delivery method aims to relieve pain while addressing the underlying disease process, offering a novel approach for patients living with painful knee osteoarthritis (搜索).
"4P004 (搜索), a GLP-1 receptor (搜索) agonist administered intra-articularly, allows specific targeting of the diseased joint and joint tissues, aiming to relieve pain while also addressing the underlying disease process, thus offering an exciting novel approach for patients living with painful knee osteoarthritis (搜索)," said Thomas J. Schnitzer, MD, PhD, Professor of Medicine at Northwestern University and U.S. Coordinating Investigator for the study.
INFLAM MOTION Trial Design
The INFLAM MOTION trial is designed as a 3-month, multicenter, randomized, double-blind, placebo-controlled Phase 2a study that will enroll 129 patients suffering from knee osteoarthritis (搜索) with synovitis (搜索). The trial incorporates multiple assessment components:
- Pain assessment at Week 4 as the primary endpoint
- Pain, function, and contrast-enhanced MRI structural assessment of the synovial membrane at Week 12
- Exploratory surrogate biomarkers predictive of progression
This comprehensive combination of clinical, imaging, and biomarker elements forms the foundation for future interactions with regulatory agencies on accelerated or conditional approval pathways, strategically positioning 4P004 (搜索) within the highest-priority segment of osteoarthritis (搜索) drug development.
Regulatory Strategy and Timeline
The FDA clearance marks another strategic step in 4Moving Biotech's global clinical deployment, reinforcing the company's position in the competitive landscape of osteoarthritis (搜索) therapeutics. Professor Francis Berenbaum, MD, PhD, Chief Medical Officer of 4Moving Biotech, emphasized the significance of the regulatory progress: "The regulatory progress across three major regions underscores the scientific robustness of 4P004 (搜索). INFLAM MOTION is designed to deliver clinically meaningful pain improvement while generating high-resolution structural and biological data to guide the next stage of development. We believe 4P004 has the potential to redefine how osteoarthritis is treated."
4Moving Biotech plans to initiate patient enrollment in the United States in Q1 2026, following site activation and investigator onboarding. The clinical-stage biotechnology company, founded in 2020 as a spin-off of 4P-Pharma (搜索) and headquartered on the Pasteur Institute campus in Lille, focuses on developing disease-modifying drugs for osteoarthritis (搜索), addressing one of the world's most burdensome chronic diseases with high unmet medical needs.